Valsartan combined with piperazine ferulate tablets is generally ideal for the treatment of early hypertensive nephropathy, but it cannot be generalized. For patients with early hypertensive nephropathy, for those with urinary protein less than 1g/24h, it is recommended that the target of blood pressure control should be <130/80 mmHg; for those with urinary protein more than 1g/24h, it can be further reduced to <125/75mmHg if tolerated and patients with stable renal function. Valsartan is a long-acting angiotensin II receptor antagonist, which reduces glomerular filtration rate while lowering blood pressure, thereby reducing urinary protein and slowing the progression of kidney disease. Common adverse reactions include elevated blood creatinine, hyperkalemia, etc. Renal artery stenosis should be excluded before application, and it is recommended to monitor blood biochemistry and renal artery indexes during use. Ferulic acid piperazine tablets are anticoagulant drugs for all kinds of glomerular diseases accompanied by microscopic hematuria and hypercoagulable state, which can improve renal blood supply and improve renal function without obvious adverse reactions, and is forbidden for those who are allergic to this product. Effective control of blood pressure through the selection of renal protective antihypertensive drugs can usually prevent the progression of renal disease. Clinically, valsartan and piperazine ferulate tablets are often used in combination, with relatively satisfactory results, but attention is still paid to monitoring changes in urinary protein and blood creatinine to assess the condition. In general, blood pressure and urine protein control is stable, and the disease progresses relatively slowly, but it can not be generalized. Hypertensive nephropathy patients mainly control blood pressure, monitor blood pressure levels, and regular regular hospital review, discomfort follow-up.